Review article · 2026 · Open access
Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook
Acta Pharmaceutica Sinica B, 16(3), 1388–1420 · Published 23 January 2026 · DOI 10.1016/j.apsb.2026.01.019
In brief
“Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook” is a 2026 review article by Xianlu Zhang and 10 co-authors, published in Acta Pharmaceutica Sinica B. OpenAlex counts 14 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Acta Pharmaceutica Sinica B.
- Citations
- 14
- Most cited in
- 2026 (14)
- Field-weighted impact
- 7.24
- References
- 309
- Authors
- 11
Abstract
Membrane-derived biomimetic nanovesicles have emerged as a promising platform in cancer immunotherapy due to their intrinsic biocompatibility, functional plasticity, and capability to modulate immune responses. By integrating various immunotherapeutic agents, including immune checkpoint inhibitors, tumor antigens, and immunostimulatory adjuvants, these vesicles can be engineered to mimic natural immune communication and overcome key barriers in the tumor immune microenvironment. This review summarizes recent advances in the design, functionalization, and application of biomimetic nanovesicles for anti-tumor immunity. We particularly highlight strategies that harness these vesicles to enhance innate and adaptive immune responses, reverse immune suppression, and synergize with existing immunotherapy modalities. Furthermore, we discuss the challenges associated with biosafety, large-scale manufacturing, and clinical translation. Continued innovation in vesicle engineering and immunological modulation will be crucial for transforming biomimetic nanovesicles into viable next-generation cancer immunotherapeutics.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zhang, X., Jing, H., Wang, Y., Mu, S., Wang, X., Zheng, H., Chen, Y., Wang, K., Sun, J., Bi, J., & Zhang, G. (2026). Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook. Acta Pharmaceutica Sinica B, 16(3), 1388–1420. https://doi.org/10.1016/j.apsb.2026.01.019
MLA 9
Zhang, Xianlu, et al. “Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.” Acta Pharmaceutica Sinica B, vol. 16, no. 3, 2026, pp. 1388–1420. https://doi.org/10.1016/j.apsb.2026.01.019.
Chicago
Zhang, Xianlu, Hongwei Jing, Yiyang Wang, Siyu Mu, Xia Wang, Haoyuan Zheng, Yiming Chen, et al. 2026. “Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.” Acta Pharmaceutica Sinica B 16 (3): 1388–1420. https://doi.org/10.1016/j.apsb.2026.01.019.
Harvard
Zhang, X. et al. (2026) ‘Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook’, Acta Pharmaceutica Sinica B, 16(3), pp. 1388–1420. doi:10.1016/j.apsb.2026.01.019.
IEEE
X. Zhang et al., “Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook,” Acta Pharmaceutica Sinica B, vol. 16, no. 3, pp. 1388–1420, 2026, doi: 10.1016/j.apsb.2026.01.019.
BibTeX
@article{zhang2026membrane,
title = {{Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook}},
author = {Zhang, Xianlu and Jing, Hongwei and Wang, Yiyang and Mu, Siyu and Wang, Xia and Zheng, Haoyuan and Chen, Yiming and Wang, Kaiyuan and Sun, Jin and Bi, Jianbin and Zhang, Gejun},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {3},
pages = {1388--1420},
doi = {10.1016/j.apsb.2026.01.019},
url = {https://doi.org/10.1016/j.apsb.2026.01.019}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- biomimetic nanovesicles
- cancer immunotherapy
- tumor immune microenvironment
- immune checkpoint inhibitors
- tumor antigens
- immunostimulatory adjuvants
- innate and adaptive immunity
- vesicle engineering
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Zhang, X., Jing, H., Wang, Y., Mu, S., Wang, X., Zheng, H., Chen, Y., Wang, K., Sun, J., Bi, J., & Zhang, G. (2026). Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook. Acta Pharmaceutica Sinica B, 16(3), 1388–1420. https://doi.org/10.1016/j.apsb.2026.01.019
How many times has this paper been cited?
14 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Acta Pharmaceutica Sinica B: sign in and open the full text from this page.
Who wrote this paper?
Xianlu Zhang, Hongwei Jing, Yiyang Wang, Siyu Mu, Xia Wang, Haoyuan Zheng, Yiming Chen, Kaiyuan Wang, Jin Sun, Jianbin Bi, Gejun Zhang.
What is the DOI of this paper?
10.1016/j.apsb.2026.01.019, permanently at https://doi.org/10.1016/j.apsb.2026.01.019. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.